EE03778B1 - Vähivaktsiin ja selle valmistamismeetod - Google Patents

Vähivaktsiin ja selle valmistamismeetod

Info

Publication number
EE03778B1
EE03778B1 EE9800161A EE9800161A EE03778B1 EE 03778 B1 EE03778 B1 EE 03778B1 EE 9800161 A EE9800161 A EE 9800161A EE 9800161 A EE9800161 A EE 9800161A EE 03778 B1 EE03778 B1 EE 03778B1
Authority
EE
Estonia
Prior art keywords
preparation
cancer vaccine
vaccine
cancer
Prior art date
Application number
EE9800161A
Other languages
English (en)
Other versions
EE9800161A (et
Inventor
Schmidt Walter
L. Birnstiel Max
Schweighoffer Tam�s
Steinlein Peter
Buschle Michael
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800161A publication Critical patent/EE9800161A/et
Publication of EE03778B1 publication Critical patent/EE03778B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9800161A 1995-11-23 1996-11-21 Vähivaktsiin ja selle valmistamismeetod EE03778B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
PCT/EP1996/005126 WO1997019169A1 (de) 1995-11-23 1996-11-21 Tumorvakzine und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EE9800161A EE9800161A (et) 1998-12-15
EE03778B1 true EE03778B1 (et) 2002-06-17

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800161A EE03778B1 (et) 1995-11-23 1996-11-21 Vähivaktsiin ja selle valmistamismeetod

Country Status (24)

Country Link
US (1) US20020085997A1 (et)
EP (1) EP0866851A1 (et)
JP (1) JP2000502052A (et)
KR (1) KR19990067653A (et)
CN (1) CN1202931A (et)
AR (1) AR004341A1 (et)
AU (1) AU720131B2 (et)
BG (1) BG62999B1 (et)
BR (1) BR9611466A (et)
CA (1) CA2238176A1 (et)
CO (1) CO4520254A1 (et)
CZ (1) CZ158998A3 (et)
EE (1) EE03778B1 (et)
HU (1) HUP0000318A3 (et)
NO (1) NO982329D0 (et)
NZ (1) NZ322910A (et)
PL (1) PL188537B1 (et)
RO (1) RO115275B1 (et)
RU (1) RU2206329C2 (et)
SK (1) SK66998A3 (et)
TR (1) TR199800912T2 (et)
TW (1) TW514530B (et)
UY (2) UY24367A1 (et)
WO (1) WO1997019169A1 (et)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
CA2278678A1 (en) * 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
ATE284707T1 (de) * 1997-08-22 2005-01-15 Science Park Raf S P A Tumorvakzinierung mittels verwendung autologer oder hla-verwandter antigen präsentierender zellen (apc), die mit einem tumorantigen sowie einem eine immunantwort hervorrufenden fremdantigen transduziert sind
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
WO2003025569A1 (fr) * 2001-09-18 2003-03-27 Kyogo Itoh Procede de detection de l'immunite cellulaire et son application sur des medicaments
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
AU2004268001B2 (en) * 2003-08-25 2010-04-22 Univax, Llc Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
PT1806358E (pt) * 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
CN104662171B (zh) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
JP2024511950A (ja) * 2021-03-12 2024-03-18 ティー－キュア バイオサイエンス，インコーポレイテッド Ｔｃｒ－ｔ療法に対する腫瘍細胞の感受性を広げるための腫瘍におけるｈｌａハプロタイプ発現の多様性の増強方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0569678A3 (en) * 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.

Also Published As

Publication number Publication date
TW514530B (en) 2002-12-21
JP2000502052A (ja) 2000-02-22
US20020085997A1 (en) 2002-07-04
RU2206329C2 (ru) 2003-06-20
SK66998A3 (en) 1998-12-02
CO4520254A1 (es) 1997-10-15
AU720131B2 (en) 2000-05-25
BG62999B1 (bg) 2001-01-31
RO115275B1 (ro) 1999-12-30
AR004341A1 (es) 1998-11-04
NO982329D0 (no) 1998-05-22
EE9800161A (et) 1998-12-15
WO1997019169A1 (de) 1997-05-29
PL188537B1 (pl) 2005-02-28
BG102439A (en) 1999-01-29
KR19990067653A (ko) 1999-08-25
HUP0000318A3 (en) 2002-02-28
UY24367A1 (es) 2000-10-31
EP0866851A1 (de) 1998-09-30
NZ322910A (en) 2000-05-26
UY24430A1 (es) 1997-07-01
AU7694796A (en) 1997-06-11
BR9611466A (pt) 1999-05-18
TR199800912T2 (xx) 1998-08-21
CN1202931A (zh) 1998-12-23
CA2238176A1 (en) 1997-05-29
PL326756A1 (en) 1998-10-26
HUP0000318A2 (hu) 2000-06-28
CZ158998A3 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
EE03778B1 (et) Vähivaktsiin ja selle valmistamismeetod
FI951340A0 (fi) SOI-substraatti ja menetelmä sen valmistamiseksi
EE9900014A (et) Erütromütsiinid ja nende valmistamise protsess
EE03409B1 (et) Kõrge efektiivsusega segusti ja selle valmistamise meetod
FI941137A (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI973378A (fi) Laite ja menetelmä
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
EE9700318A (et) Optiline seade ja meetod
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
FI98529B (fi) Menetelmä ja laitteisto keveiden olefiinien valmistamiseksi
KR960007649A (ko) 공중합 폴리아미드 및 그의 제조방법
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
BR9602983A (pt) Gel e processo para sua preparação
FI952229A (fi) Kuumuutta kestävä hiusvalmiste ja menetelmä sen käyttämiseksi
EE03738B1 (et) Hambaimplantaatsüsteem ja meetod selle valmistamiseks
DE69629457D1 (de) Impfstoff in gelform
FI964310A (fi) Imidatsolijohdannainen ja menetelmä sen valmistamiseksi
ATE253641T1 (de) Antigenische präparationen
DK0826679T3 (da) Naphthylforbindelser og -præparater
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
BR9708979A (pt) Complexo imunogénico utilização do mesmo vacina processo para a preparação de um complexo imunogenico e utilização de uma proteína
FI940403A (fi) Elliptisiinijohdannainen ja menetelmä sen valmistamiseksi
FI963330A (fi) Menetelmä ja järjestelmä ainesseoksesta tapahtuvaa näytteenottoa varten
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20041121